Savant Capital LLC Decreases Holdings in DaVita Inc. $DVA

Savant Capital LLC reduced its position in DaVita Inc. (NYSE:DVA) by 48.4% in the 4th quarter, Holdings Channel reports. The firm owned 4,640 shares of the company’s stock after selling 4,355 shares during the period. Savant Capital LLC’s holdings in DaVita were worth $527,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in DVA. NewEdge Advisors LLC lifted its holdings in shares of DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after purchasing an additional 88 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of DaVita by 19.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock valued at $27,403,000 after purchasing an additional 28,739 shares during the last quarter. Cerity Partners LLC lifted its holdings in shares of DaVita by 7.0% in the 2nd quarter. Cerity Partners LLC now owns 2,638 shares of the company’s stock valued at $376,000 after purchasing an additional 172 shares during the last quarter. Bank of Nova Scotia lifted its holdings in shares of DaVita by 3.8% in the 2nd quarter. Bank of Nova Scotia now owns 4,813 shares of the company’s stock valued at $686,000 after purchasing an additional 176 shares during the last quarter. Finally, Natixis lifted its holdings in shares of DaVita by 80.9% in the 2nd quarter. Natixis now owns 7,297 shares of the company’s stock valued at $1,039,000 after purchasing an additional 3,264 shares during the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Stock Down 1.5%

Shares of DVA stock opened at $192.14 on Friday. The stock has a market capitalization of $12.34 billion, a PE ratio of 17.82, a price-to-earnings-growth ratio of 0.64 and a beta of 0.91. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $202.69. The stock’s 50-day moving average price is $170.73 and its 200 day moving average price is $142.83.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.33 by $0.54. The firm had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The firm’s revenue for the quarter was up 6.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Analysts expect that DaVita Inc. will post 15.07 earnings per share for the current fiscal year.

Insider Transactions at DaVita

In related news, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the transaction, the chief financial officer owned 132,434 shares in the company, valued at $25,440,571.40. The trade was a 27.99% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

DVA has been the subject of several research reports. TD Cowen boosted their target price on DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a report on Monday, May 11th. Deutsche Bank Aktiengesellschaft raised DaVita from a “hold” rating to a “buy” rating and boosted their target price for the company from $126.00 to $220.00 in a report on Wednesday, May 6th. Zacks Research raised DaVita from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Barclays boosted their target price on DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Finally, UBS Group boosted their price target on DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $199.17.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.